StemCell Therapy

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial, is being presented at a Spotlight Poster Discussion Session by Frankie Ann Holmes, M.D., FACP, Texas Oncology Houston US Oncology Research, an investigator of the trial. A copy of this poster presentation is available on the Puma website.

ExteNET was a multicenter, randomized, double-blind, Phase III trial of 2,840 HER2-positive eBC patients who received neratinib after neoadjuvant and/or adjuvant therapy with chemotherapy and trastuzumab. Patients were stratified by hormone receptor status and randomly assigned to one year of treatment with either oral neratinib 240 mg/day or placebo. The primary endpoint of the trial was invasive disease-free survival (iDFS). Secondary endpoints include overall survival and cumulative incidence of CNS metastases. A descriptive analysis that evaluated CNS disease free survival, which was defined as time from randomization to any CNS recurrence or death from any cause, was performed.

Within the European Union, neratinib is approved in patients with hormone receptor positive (HR+) breast cancer who initiated treatment within one year of completing an adjuvant trastuzumab containing regimen.

The endpoints were analyzed for three groups of clinical interest: (i) the intent to treat (ITT) population; (ii) patients with HR+ breast cancer who initiated treatment within one year of completing an adjuvant trastuzumab containing regimen; and (iii) patients with HR+ breast cancer who initiated treatment within one year of completing an adjuvant trastuzumab containing regimen and who did not achieve a pathological complete response (no pCR) after neoadjuvant treatment and therefore were at a high risk of disease recurrence. Results from the Phase III ExteNET trial were published in the October 5, 2020 issue of Clinical Breast Cancer. The manuscript is accessible online at https://www.clinical-breast-cancer.com/article/S1526-8209(20)30258-5/fulltext.

In the ITT population, 127 of 1420 patients (8.9%) in the neratinib group and 137 of 1420 patients (9.6%) in the placebo group died, as of the analysis cut-off date (July 2019). The estimated 8-year overall survival (OS) rates were 90.1% in the neratinib group and 90.2% in the placebo group (stratified HR 0.95; 95% confidence interval [CI] 0.75-1.21; p=0.69). The cumulative incidence of CNS metastases at 5 years was 1.3% (95% CI 0.8-2.1) in the neratinib arm and 1.8% (95% CI 1.2-2.7%) in the placebo arm, while the estimated CNS disease free survival at 5 years was 97.5% in the neratinib group and 96.4% in the placebo group (stratified HR 0.73; 95% CI 0.45-1.17).

In the HR+ /< 1 yr patient population, 53 of 670 patients (7.9%) in the neratinib group and 68 of 664 patients (10.2%) in the placebo group died. The estimated 8-year OS rates were 91.5% in the neratinib group and 89.4% in the placebo group, corresponding to a 2.1% absolute benefit (HR 0.79; 95% CI 0.551.13). The cumulative incidence of CNS metastases at 5 years was 0.7% (95% CI 0.2-1.7) in the neratinib arm and 2.1% (95% CI 1.1-3.5) in the placebo arm, while the estimated CNS disease free survival at 5 years was 98.4% in the neratinib group and 95.7% in the placebo group (stratified HR 0.41; 95% CI 0.18-0.85).

In the HR+/ <1 yr, no pCR subgroup of patients (n=295), 8-year OS rates were 91.3% in the neratinib group and 82.2% in the placebo group, corresponding to a 9.1% absolute benefit (HR 0.47; 95% CI 0.230.92). In the HR+/ <1 yr, with a pCR (n=38), 8-year OS rates were 93.3% in the neratinib group and 73.7% in the placebo group, corresponding to a 19.6% absolute benefit (HR 0.40; 95% CI 0.061.88). The cumulative incidence of CNS metastases at 5 years was 0.8% (95% CI 0.1-4.0) in the neratinib arm and 3.6% (95% CI 1.3-7.8%) in the placebo arm, while the estimated CNS disease free survival at 5 years was 98.4% in the neratinib group and 92.0% in the placebo group (stratified HR 0.24; 95% CI 0.04-0.92).

Dr. Frankie Ann Holmes said, These descriptive analyses in HR+ patients who received neratinib within one year of completing trastuzumab and did not achieve a pCR post neoadjuvant therapy suggest that neratinib may be associated with improved OS in this high-risk group (HR 0.47, absolute benefit 9.1%). Importantly, neratinib is the first HER2-directed agent to show a trend towards improved CNS outcomes in early stage HER2-positive breast cancer, with consistently fewer CNS events observed in the neratinib arm compared with placebo in all groups evaluated.

Alan H. Auerbach, Chief Executive Officer and President of Puma, added, Descriptive analyses suggest that neratinib may be associated with longer overall survival in subgroups of clinical interest and in the high-risk patient subgroup with residual disease after neoadjuvant therapy who are at a high risk of disease recurrence. Although there have been many new treatment options for patients with early stage HER2-positive breast cancer, the risk of disease recurrence and more specifically CNS recurrence remains significant and more must be done. These newly published data demonstrate that neratinib provides a clinically meaningful reduction in the risk of recurrence and CNS recurrence and provides a very important option for these high risk patients.

About HER2-Positive Breast Cancer

Up to 20% of patients with breast cancer tumors over-express the HER2 protein (HER2-positive disease) and in the ExteNET study, 57% of patients were found to have tumors that were hormone-receptor positive. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer recurring, up to 25% of patients treated with trastuzumab experience recurrence within 10 years, the majority of which are metastatic recurrences.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Lactation: Advise women not to breastfeed.

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

Read the original here:
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS - Business Wire

A rating of 79 puts Trevena Inc (TRVN) near the top of the Biotechnology industry according to InvestorsObserver. Trevena Inc's score of 79 means it scores higher than 79% of stocks in the industry. Trevena Inc also received an overall rating of 63, putting it above 63% of all stocks. Biotechnology is ranked 34 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Trevena Inc (TRVN) stock is trading at $2.21 as of 10:49 AM on Tuesday, Dec 8, a drop of -$0.06, or -2.71% from the previous closing price of $2.27. The stock has traded between $2.15 and $2.25 so far today. Volume today is below average. So far 1,752,356 shares have traded compared to average volume of 4,048,084 shares.

Click Here to get the full Stock Score Report on Trevena Inc (TRVN) Stock.

Go here to read the rest:
Is Trevena Inc (TRVN) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 62 rating InvestorsObserver gives to Cellectar Biosciences Inc (CLRB) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 78 percent of stocks in the Biotechnology industry, CLRBs 62 overall rating means the stock scores better than 62 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Cellectar Biosciences Inc (CLRB) stock is trading at $2.25 as of 10:49 AM on Tuesday, Dec 8, a drop of -$0.10, or -4.26% from the previous closing price of $2.35. The stock has traded between $2.06 and $2.35 so far today. Volume today is light. So far 973,567 shares have traded compared to average volume of 1,538,630 shares.

Click Here to get the full Stock Score Report on Cellectar Biosciences Inc (CLRB) Stock.

Continued here:
Is Cellectar Biosciences Inc (CLRB) a Winner in the Biotechnology Industry? - InvestorsObserver

The 65 rating InvestorsObserver gives to BioNTech SE - ADR (BNTX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, BNTXs 65 overall rating means the stock scores better than 65 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 65 means the stock is more attractive than 65 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

BioNTech SE - ADR (BNTX) stock is up 2.67% while the S&P 500 is lower by -0.18% as of 10:49 AM on Tuesday, Dec 8. BNTX is higher by $3.35 from the previous closing price of $125.70 on volume of 2,210,886 shares. Over the past year the S&P 500 has gained 17.52% while BNTX is higher by 345.03%. BNTX lost -$1.01 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BioNTech SE - ADR (BNTX) Stock.

Read the original:
Is BioNTech SE - ADR (BNTX) the Top Pick in the Biotechnology Industry? - InvestorsObserver

BioXcel Therapeutics Inc (BTAI) is near the top in its industry group according to InvestorsObserver. BTAI gets an overall rating of 63. That means it scores higher than 63 percent of stocks. BioXcel Therapeutics Inc gets a 79 rank in the Biotechnology industry. Biotechnology is number 36 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 63 would rank higher than 63 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

BioXcel Therapeutics Inc (BTAI) stock is up 3.5% while the S&P 500 is down -0.39% as of 2:26 PM on Monday, Dec 7. BTAI is higher by $1.60 from the previous closing price of $45.70 on volume of 185,902 shares. Over the past year the S&P 500 is higher by 17.49% while BTAI is higher by 667.86%. BTAI lost -$3.37 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BioXcel Therapeutics Inc (BTAI) Stock.

See the original post:
Should You Buy BioXcel Therapeutics Inc (BTAI) in Biotechnology Industry? - InvestorsObserver

A grant from the federal Department of Education will improve resources in the school's Center for Biotechnology and also reach out to students in grades K-12.

FORT VALLEY, Ga. A new grant could help bring in more biotechnology students to Fort Valley State University.

Dr. Sarwan Dhir is the director for the Center of Biotechnology. He says for the next three years, the program at Fort Valley State University will have a new grant.

"In the last 20 years, biotechnology has changed the whole world," says Dhir.

"Right now, an example is that pharmaceutical and biotech companies are working together to solve the problem of COVID-19," he says.

Dhir says the grant is for almost $750,000, and it comes from the U.S. Department of Education.

He says it will not only help with tuition costs for current Wildcats, but also work to raise interest in biotechnology for elementary, middle, and high school aged kids.

"The grant is basically going to recruit 15 students and keep them for three years, but on top of that, we have another grant from the national science foundation that is actually going to provide them with the scholarship for $17,000 for four years," says Dhir.

There are currently 45 students in the program, and one of them is senior Tori McGuire, who says she's ready to start a Master's program next.

"I appreciate the money that he has set up and the money that he brings into here because I really haven't had this chance to have opportunities like this," she says about Dhir.

Freshman Dakota Walker says she came into the university as a marketing major, but soon changed majors after meeting Dhir. She says for students considering majoring in biotechnology, Fort Valley State is the only option.

"Plain and simple, because we're the best. There is no denying that. We're 100 percent the best, we have the resources, we have the faculty, we have a staff that wants to help you, we want to see you succeed," she says.

Dhir says to start, all programs and workshops will be virtual.

Continue reading here:
'Biotechnology has changed the world': Fort Valley State University receives grant to attract biotech majors - 13WMAZ.com

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, and WhyWeVax (WWV), a non-profit organization dedicated to building vaccine confidence, workforce security and countering vaccine misinformation, announced that executives from both organizations recently made public comments discussing the science of COVID-19 vaccines and the challenges of vaccine hesitancy and distribution.

Sia Anagnostou, Senior Director of Corporate Development for ITI and WWV Board Secretary, recently made public comments during the ACIP emergency meeting in support of the CDCs recommendation to allocate the initial COVID vaccine doses expected late Dec 2020 - Jan 2021 to health care workers and people living in long-term care facilities. In addition to the ACIP discussion, Dr. William Hearl, CEO of ITI and Chairman of WWV, was interviewed on Fox News 29 in Philadelphia to amplify the commentary on these topics.

It is important that leaders in the biotechnology community speak out wherever possible to effectively communicate the value, safety and efficacy of vaccines for COVID-19 and other infectious diseases, said Dr. Hearl. Participation in immunization education and support of Public Health efforts is of the utmost importance as we face the global challenge of this pandemic.

The public comments at ACIP and on Fox News are available here:

https://www.fox29.com/video/876822.amp

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that have the potential to generate broad immune responses. The UNITE platform has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including targeting viral antigens, cancer antigens, neoantigens and producing antigen-derived antibodies as biologics. In early 2020, an investment of over $60M by HLB Co., LTD, a global pharmaceutical company, enabled ITI to accelerate application of its immuno-oncology platform, in particular to glioblastoma multiforme, and rapidly advance other key candidates in the pipeline, including the most recent initiative into infectious diseases with development of its vaccine candidate for COVID-19. The Company has built a large pipeline from UNITE with eight oncology programs, multiple animal health programs and a SARS-CoV-2 program to prevent and treat COVID-19. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Duke University and the University of Florida. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit http://www.immunomix.com.

About Why We Vaccinate, Inc.

WhyWeVax - http://www.whywevax.org - is a 501(3)(c) educational organization dedicated to provide a credible and trusted source for honest and factual information on vaccines, their efficacy, safety and importance to public health. WhyWeVax works to counter the misinformation, anti-science rhetoric and virulent fake news dissemination that question the safety and efficacy of vaccines for preventable infectious diseases. The development of a safe and effective vaccine for COVID-19 and its ultimate manufacture and distribution through the healthcare system will require a concerted effort by the biotechnology, academic, medical and scientific communities to meet the challenge of vaccine hesitancy and refusal. WhyWeVax will support educate the population to the value of vaccines to protect the health and safety of their families, their friends, their communities and our way of life.

See the original post here:
Immunomic Therapeutics Executives and Board Members of WhyWeVax Discuss COVID-19 Vaccine Issues with Fox News and CDC's ACIP Committee - Business Wire

Galectin Therapeutics Inc. Common Stock (GALT) is near the top in its industry group according to InvestorsObserver. GALT gets an overall rating of 60. That means it scores higher than 60 percent of stocks. Galectin Therapeutics Inc. Common Stock gets a 75 rank in the Biotechnology industry. Biotechnology is number 34 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 60 would rank higher than 60 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Galectin Therapeutics Inc. Common Stock (GALT) stock is trading at $2.67 as of 10:41 AM on Tuesday, Dec 8, a loss of -$0.08, or -2.91% from the previous closing price of $2.75. The stock has traded between $2.62 and $2.71 so far today. Volume today is light. So far 75,489 shares have traded compared to average volume of 172,918 shares.

Click Here to get the full Stock Score Report on Galectin Therapeutics Inc. Common Stock (GALT) Stock.

Here is the original post:
Is Galectin Therapeutics Inc. Common Stock (GALT) The Right Choice in Biotechnology? - InvestorsObserver

The Narendra Modi-led Central government has announced that the second campus of the Rajiv Gandhi Centre for Biotechnology (RGCBT) in Thiruvananthapuram, Kerala, a premier molecular biology and biotechnology research centre now under the Ministry of Science and Technology, will be named after M.S. Golwalkar, the Rashtriya Swayamsewak Sangh (RSS) ideologue.

The announcement, made by Union Minister for Science and Technology Dr Harsh Vardhan on December 4 during his online address to the pre-inaugural session of the sixth edition of the International Science Festival, has taken Kerala by surprise.

The RGCBT had earlier announced that its second campus would be named the Centre for Complex Diseases in Cancer and Viral Infections.

Harsh Vardhans statement that the new campus is to be named "Shri Guruji Madhav Sadashiv Golwalkar National Centre for Complex Diseases in Cancer and Viral Infections", apparently as decided by the RGCBT governing body, has come without notice to or prior consultation with the State government, which originally established the RGCBT as a research & development centre. The State had subsequently handed over the centre to the Government of India for developing it as a centre of international standards in research and development.

Protests are mounting by the day in the State on the propriety of choosing to name the campus after a person whose abiding role has not been in science but in providing Hindutva forces an ideological base and an organisational structure to achieve a Hindu Rashtra.

The Bharatiya Janata Party (BJP) political leadership has come up with rather strange arguments to justify the move: (a) Golwalkar has an M.Sc. in Zoology and he left his studies while doing a Ph.D. in Marine Biology to become an active member of the RSS; (b) that he had a great vision about the scientific development of the country and his teachings and ideas are relevant in the present time; (c) the Left has given the names of several communist leaders jailed in 1947 and 1962 for anti-national activities to several institutions; (d) the Communist Party of India (Marxist) should explain the basis for naming a football stadium in Kozhikode after E.M.S. Namboodiripad; and (e) why is the renowned annual Nehru Trophy Boat Race in Kerala named after Jawaharlal Nehru? (the last question was raised as a justification by V. Muraleedharan, the Union Minister of State for External Affairs and Parliamentary Affairs).

The ruling and opposition parties in Kerala find themselves united as an offshoot of the controversy. Almost all political parties except the BJP have condemned the announcement to name the new campus after the RSS ideologue.

While Chief Minister Pinarayi Vijayan, in a letter to Union Minister Harsh Vardhan, suggested that the new campus should be named after some eminent Indian scientist of international repute, Opposition Leader Ramesh Chennithala said in a letter to Prime Minister Narendra Modi that the new campus should continue to function under the name of former Prime Minister Rajiv Gandhi.

Sashi Tharoor, MP from Thiruvananthapuram, said in a series of tweets on Twitter: What is MSGs [M.S. Golwalkar] contribution to science other than promoting the disease of communalism?; I suggest a local hero: Dr. P. Palpu, renowned bacteriologist and social reformer, born in Thiruvananthapuram in the year 1863. Expert in serum therapy and tropical medicine from Cambridge, Director of the Vaccine Institute and Fellow of the Royal Institute of Public Health. This forward-looking scientist and medical practitioner would be far more appropriate than an obscurantist ideologue of no scientific achievement and no discernible contribution to public health. Its a BJP insult to Thiruvananthapuram and should be resisted.

The Modi governments move cannot be seen in isolation, coming as it does after similar controversies over pleas for rewriting history from an Indian standpoint, the unveiling of the V.D. Sarvarkar portrait at the Central Hall of Parliament and the eulogisation in school textbooks and through the naming or renaming of airports, railway stations, bridges, streets and flyovers after Hindutvas other heroes such as K.B. Hedgewar and Deen Dayal Upadhyaya.

Moreover, if statements by V. Muraleedharan and other BJP leaders are any indication, the name Shri Guruji Madhav Sadashiv Golwalkar National Centre for Complex Diseases in Cancer and Viral Infections has been presented as a fait accompli and, significantly, as a strong political message in Left Front-ruled Kerala where the BJP has so far been unable to make much gains. It is also significant that the RGCBTs prestigious new campus also is in Thiruvananthapuram, where the BJP is hoping to make some significant gains in the ongoing local body elections and in the Assembly elections that is to follow soon.

For more on Golwalkar, read: What is Hindu Rashtra?

Read more:
Protests erupt in Kerala over the Central governments decision to name the second campus of the Rajiv Gandhi Centre for Biotechnology in...

New Jersey, United States,-

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: An analysis for future growth

Global Nanoparticles in Biotechnology and Pharmaceuticals Market report has added committed areas covering the tendencies of the target crowd and the opposition as of now present on the lookout. Because of the COVID-19 pandemic, numerous organizations have confronted a colossal plunge in their functions and sales. However, the Global Nanoparticles in Biotechnology and Pharmaceuticals market has pushed through this unpleasant market fix and came out with brilliant outcomes. This has pulled in the consideration of large organizations as well as the new companies too, to attempt their hands in one of the steadiest markets.

To comprehend the market elements and mainstays of the Global Nanoparticles in Biotechnology and Pharmaceuticals market, the report helps in unwinding the insider facts behind the consistent development of the market since initiation. Factors, for example, political situation, segments focal points and tendency of target crowd are a portion of the main considerations that either drive the business forward or pull them down.

Request Sample Copy of this Report @ Nanoparticles in Biotechnology and Pharmaceuticals Market Size

In market segmentation by manufacturers, the report covers the following companies-

Why is it important to understand the post-COVID19 Global Nanoparticles in Biotechnology and Pharmaceuticals -market?

The capital inflow and outpouring of the Global Nanoparticles in Biotechnology and Pharmaceuticals -market is consistent in any event, during the progressing pandemic, pushing it as one of the most solid organizations during the ongoing occasions. To measure the market openings, customers can exploit the recommendable activities pointed in the report. These activities are attempted and tried prior to imparting to customers to set aside their time and cash.

How to overcome obstacles for the septennial 2020-2027 using the Global Nanoparticles in Biotechnology and Pharmaceuticals market report?

Presently, going to the main part-outside elements. Porters five powers are the main components to be thought of while moving into new business markets. The customers get the opportunity to use the approaches to plan the field-tested strategies without any preparation for the impending monetary years.

We have faith in our services and the data we share with our esteemed customers. In this way, we have done long periods of examination and top to bottom investigation of the Globalmarket to give out profound bits of knowledge about the Global Nanoparticles in Biotechnology and Pharmaceuticals market. Along these lines, the customers are enabled with the instruments of data (as far as raw numbers are concerned).

The graphs, diagrams and infographics are utilized to speak out about the market drifts that have formed the market. Past patterns uncover the market turbulences and the final results on the markets. Then again, the investigation of latest things uncovered the ways, the organizations must take for shaping themselves to line up with the market.

What type of data is added into the Global Nanoparticles in Biotechnology and Pharmaceuticals market report?

Working corresponding to the market can be troublesome however not with the direction from the Global Nanoparticles in Biotechnology and Pharmaceuticals market report. The report shares the data gathered from the official sites of the administering bodies and the yearly reports of the current market players. Making the report reliable and trustworthy. Thusly, the market can be perceived from its foundations.

To accomplish greatest ROI alongside increasing most extreme lump of the market, the customers can use the information from the Global Nanoparticles in Biotechnology and Pharmaceuticals market report. The report gives step-wise strategies to accomplish for transient objectives. For understanding the drawn out objectives, the report grandstands the advantages of dealing with the partners and the encompassing individuals on the lookout. This will help the business endeavours in coming out with brilliant numbers.

What are the advantages of using Global Nanoparticles in Biotechnology and Pharmaceuticals market report?

The opponents referenced in the report are added for instance purposes and can be changed according to the prerequisites set forward by the customers. Advantages related with Global Nanoparticles in Biotechnology and Pharmaceuticals market report are recorded underneath:

1. Long-term and momentary investigation of the objectives for the customers. 2. In-profundity investigation of the inside and outside elements affecting the organizations development. 3. Exploring the socioeconomics best appropriate for venturing into the new market. 4. Examination of patterns through trials for outlining powerful and proficient strategies. 5. Ways to raise capital for smooth working of the associations business. 6. Working parallel to the market through proper SWOT and PESTLE examinations.

Have Any Query? Ask Our Expert @ Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

About us:

Market Research Blogs is a leading Global Research and Consulting firm servicing over 5000+ customers. Market Research Blogs provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Get More Market Research Report Click @ Market Research Blogs

See original here:
Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Share, Growth, Trends, Outlook, Scope and Forecast to 2027 - The Haitian-Caribbean...

Market Study Report, LLC adds latest research report on Food Biotechnology Industry Market, which delivers a comprehensive study on current industry trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its growth trends and competitive landscape as well as the key players in the business.

This Food Biotechnology Industry market research study is a collection of insights that translate into a gist of this industry. It is explained in terms of a plethora of factors, some of which include the present scenario of this marketplace in tandem with the industry scenario over the forecast timeframe.

Request a sample Report of Food Biotechnology Industry Market at:https://www.marketstudyreport.com/request-a-sample/2727907?utm_source=cheshire.media&utm_medium=Ram

The report is also inclusive of some of the major development trends that characterize the Food Biotechnology Industry market. A comprehensive document in itself, the Food Biotechnology Industry market research study also contains numerous other pointers such as the current industry policies in conjunction with the topographical industry layout characteristics. Also, the Food Biotechnology Industry market study is comprised of parameters such as the impact of the current market scenario on investors.

The pros and cons of the enterprise products, a detailed scientific analysis pertaining to the raw material as well as industry downstream buyers, in conjunction with a gist of the enterprise competition trends are some of the other aspects included in this report.

How has the competitive landscape of this industry been categorized?

, as per the report.

Regional landscape: How will the details provided in the report help prominent stakeholders?

Ask for Discount on Food Biotechnology Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2727907?utm_source=cheshire.media&utm_medium=Ram

Other pivotal aspects encompassed in the Food Biotechnology Industry market study:

.

.

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-food-biotechnology-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. Global Sales Forecasting Software Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-sales-forecasting-software-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

2. Global Application Performance Monitoring (APM) Suites Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-application-performance-monitoring-apm-suites-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Read More Reports On: https://www.marketwatch.com/press-release/copper-chlorophyll-market-segmented-by-product-top-manufacturers-geography-trends-forecasts-to-2025-2020-12-03

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the article here:
Food Biotechnology Industry Market Growth Projection from 2020 to 2026 - Cheshire Media

Text size

The tiny Vir Biotechnology was vaulted from obscurity this year, when it said it was developing treatments for Covid-19. Its stock (ticker: VIR) shot from $12 to a March peak of $75, before settling back to the mid-30swhere GlaxoSmithKline (GSK) bought a $250 million stake.

Vir started clinical trials in August for its antibody treatment against Covid-19. But the train has left the station, says Baird analyst Madhu Kumar, and Vir may have missed its Covid business opportunity. Antibodies from Eli Lilly (LLY) and Regeneron Pharmaceutical (REGN) have already gotten emergency use authorizations from regulators and booked orders. Demand for any Covid-19 treatment will start to shrink with the imminent authorization of vaccines from Pfizer (PFE), BioNTech (BNTX) and Moderna (MRNA).

In a Thursday note, Kumar reiterated his Underperform rating for Vir stock, whose shares he thinks should fall to $24 from their recent level near $32.

The Baird analyst went to a sell rating after Virs initial jump in February, and has maintained steady criticism since, in nearly 40 notes. Vir could find success with another treatment it is testing against hepatitis B, says Kumar, but future sales of such a product would only be worth $14 in current value. Ascribing $3.50 in value for Virs other pipeline programs, and counting its $6.50 a share in cash, brings Kumar to his $24 fair value.

Antibodies from Regeneron were among the treatments given to President Donald Trump in October, when he got Covid.

Newsletter Sign-up

Every weekday evening we highlight the consequential market news of the day and explain what's likely to matter tomorrow.

Virs securities filings say that its Covid-19 antibody trial could produce interim results in January 2021, and a final readout later in that years first quarter. The Baird analyst doesnt expect an authorization and product launch until the springby which point vaccines should be getting into wide supply.

Meanwhile, the bridging opportunity for anti-Covid antibodies is being snapped up by Lilly and Regeneron. The U.S. government arranged to buy 950,000 doses of Lillys treatment, including a deal for 650,000 doses announced Wednesday that will bring $850 million to Lilly.

Write to Bill Alpert at william.alpert@barrons.com

View original post here:
Vaccines and Approved Antibodies Could Dim Vir Biotechnologys Covid Opportunity - Barron's

Maharashtra

DistrictCases

Mumbai45,478

Thane13,660

Pune9,920

Mumbai Suburban5,363

Aurangabad1,974

Nashik1,575

Raigad1,462

Palghar1,421

Solapur1,291

Jalgaon1,039

Akola757

Nagpur692

Kolhapur646

Satara629

Ratnagiri350

Amravati291

Dhule228

Hingoli208

Jalna201

Ahmednagar190

Nanded176

Yavatmal150

Sangli145

Latur139

Osmanabad125

Sindhudurg114

Buldhana88

Parbhani78

gondia69

Beed54

Nandurbar42

Gadchiroli42

Bhandara41

Chandrapur32

Washim13

Wardha11

18,64,348 4,981

74,315 145

17,42,131 5,051

47,902 75

DistrictCases

Udupi1,176

Kalaburagi669

Yadgir538

Bengaluru Urban529

Raichur369

Mandya346

Belagavi337

Bidar219

Hassan205

Davangere204

Vijayapura201

Dakshina Kannada179

Chikkaballapura149

Mysuru107

Bagalkote103

Uttara Kannada95

Shivamogga67

Dharwad61

Ballari60

Gadag45

Bengaluru Rural40

Tumakuru36

Kolar29

Haveri24

Chikkamagaluru19

Chitradurga14

Koppal5

Kodagu4

Ramanagara3

Chamarajanagara0

8,96,563 1,279

23,075 1,959

8,61,588 3,218

11,900 20

DistrictCases

Kurnool795

Krishna557

Guntur511

Anantapur428

East Godavari356

Chittoor319

Sri Potti Sriramulu Nell*296

Y.S.R.205

West Godavari199

Srikakulam183

Prakasam104

Visakhapatnam103

Vizianagaram23

8,73,457 618

5,259 170

8,61,153 785

7,045 3

DistrictCases

Chennai23,324

Chengalpattu1,314

Thiruvallur774

Villupuram509

View original post here:
Department Of Biotechnology's Expert Committee Tracking Developments Related To COVID-19 Vaccine: Official | News - Swachh India NDTV

Analysts who follow PDS Biotechnology Corp (PDSB) on average expect it to increase 209.68% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.

That average rating earns PDSB an Analyst Ranking of 79, which means it ranks higher than 79 of stocks, based on data compiled by InvestorsObserver.

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.

InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

PDS Biotechnology Corp (PDSB) stock is trading at $2.17 as of 1:08 PM on Wednesday, Dec 9, a loss of -$0.26, or -10.7% from the previous closing price of $2.43. The stock has traded between $2.15 and $2.40 so far today. Volume today is 585,089 compared to average volume of 614,574.

Click Here to get the full report on PDS Biotechnology Corp (PDSB) Stock.

Continued here:
Analyst Rating: Will PDS Biotechnology Corp (PDSB) Stock Outperform the Market? - InvestorsObserver

A rating of 80 puts Crispr Therapeutics AG (CRSP) near the top of the Biotechnology industry according to InvestorsObserver. Crispr Therapeutics AG's score of 80 means it scores higher than 80% of stocks in the industry. Crispr Therapeutics AG also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 36 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Crispr Therapeutics AG (CRSP) stock is higher by 4.47% while the S&P 500 has fallen -0.3% as of 1:19 PM on Monday, Dec 7. CRSP is higher by $6.60 from the previous closing price of $147.54 on volume of 2,324,656 shares. Over the past year the S&P 500 has gained 17.61% while CRSP is higher by 128.52%. CRSP lost -$3.25 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

See the rest here:
Where Does Crispr Therapeutics AG (CRSP) Stock Fall in the Biotechnology Field? - InvestorsObserver

December 04, 2020

Contact: Anissa Riley, College of Veterinary Medicine

Tuskegee University College of Veterinary Medicine students recently had the opportunity to assist veterinary large animal clinicians and surgeons in the medical treatment of a social media famous patient who goes by the name, Brisket the Bull. Brisket was given a clean bill of health on December 1 from the veterinary medical teaching hospital and then released to his owner.

The eight-year old Brahman bull is owned by Judy Presley, formerly from Tennessee but now a resident of Luverne, Alabama. Presley bought Brisket at a sale barn when he was just two years old. Over the years, she has raised and trained him to accept a halter, saddle and to be ridden. Brisket has a very gentle temperament and is nationally recognized for his owner's ability to trail ride and show jump with him.

Brisket had a two-month history of an abscessed prepuce in which the abscess was treated by a private practice before being brought to the veterinary hospital for a sheath resection, which was a surgery successfully performed by Dr. Jeannine Bellamy, veterinary medical teaching hospital director, and myself providing the anesthesia, said Dr. David McKenzie, professor and large animal clinician in the Large Animal Clinical Sciences Department.

The students assisted in the medical aftercare in which Briskets healing progressed well and led to a recent successful discharge. Briskets owner Judy was very pleased with the services of the college in treating Brisket and offered to have the students take pictures with him and be shared on Briskets Facebook and fan social media pages.

We are proud of our students and thankful to our large animal veterinary medical clinicians for providing quality healthcare for our bovine clients. Being exceptional is what we are striving to be here at Tuskegee and have our clients be pleased with the veterinary services provided to our patients while preparing our students to be career-ready veterinarians upon completing the veterinary curriculum, said Dr. Ruby L. Perry, dean of the College of Veterinary Medicine.

To learn more about the College and the Tuskegee Veterinary Medical Teaching Hospital, visit http://www.tuskegee.edu/vetmed and http://www.tuskegee.edu/vetcare.

2020 Tuskegee University

See the article here:
Tuskegee University College of Veterinary Medicine treats social media famous patient Brisket the Bull - Tuskegee University

AMARILLO and LUBBOCK, Texas (NEWS RELEASE) The following is a news release from Texas Tech University:

Say the words New York and most people will think of the large, metropolitan area that is the financial and shopping center of the U.S. Few, if any, say agriculture.

Yet if you get outside of the main city, the state of New York is an important contributor of agricultural products in the country. The state has a $3.6 billion agricultural industry with more than 35,000 farms producing products from apples and cabbage to milk and cheese, grapes, maple syrup and cauliflower.

It is here where Emily Sundman was raised and saw firsthand the critical role agriculture has on the state and the importance of those who care for farm animals. This became the foundation for a career supporting animal health.

That career now brings her to West Texas as the latest member to join the faculty of the newTexas Tech School of Veterinary Medicine in Amarilloas an assistant professor of medicine. She began her duties on Tuesday (Dec. 1).

I am thrilled to join the Texas Tech School of Veterinary Medicine in time to welcome the inaugural class, Sundman said. Working at the School of Veterinary Medicine is a career dream realized in order to further veterinary care for our large animals.

Sundman has spent much of her career involved in agricultural industry research and development, inventing ways to directly and positively impact animal health and assisting practicing veterinarians who seek to do the same.

Since December 2013, Sundman has served a role in clinical development for Kindred Biosciences, which takes strategies that are safely used for human therapeutics and applies them to the development of animal biologics, such as monoclonal antibodies and recombinant proteins.

From 2013 to 2017, she oversaw the clinical development phase, including efficacy and safety, of new animal pharmaceuticals for approval by the United States Department of Agriculture (USDA), the Food and Drug Administration (FDA) and the Committee for Medicinal Products for Veterinary Use (CVMP). She also designed and executed clinical studies and was primarily responsible for pharmaceuticals for use in horses, dogs and cats.

She was promoted to Senior Clinical Development Manager in 2017, where she was responsible for the approval of Zimeta IV for use in controlling fever in horses in the U.S. She served in this role until September, when she was promoted to Associate Director of Clinical Development, increasing the responsibilities for early phase strategy and development of products for USDA and CVMP approval.

Sundman also has been co-owner and veterinarian at Picolino Ranch since 2015. The ranch, located in Lipan, Texas, specializes in the breeding and development of Aberdeen cattle, raising them to become accustomed to the pastureland and climate associated with North Texas. Since 2013, she has served as an emergency equine ambulatory veterinarian serving in Davis, California, and later the Lipan areas.

2020 has shown us the importance of innovation, saidGuy Loneragan, dean of the School of Veterinary Medicine. To help with and prevent COVID-19, the call went out for new therapies and for new vaccines. Innovative products are now arriving, and society has benefited from this research and discovery. Veterinary medicine is no different. Our animals large and small benefit from new therapies and new preventatives. Dr. Sundman will add to our schools vibrant research and discovery efforts. She also serves an important role helping our researchers design the best possible trials to test new discoveries. We are so lucky Dr. Sundman has joined our school. We will benefit so very much from what she contributes.

Sundman earned bachelors degrees in history and biology from Syracuse University and her Doctor of Veterinary Medicine from Cornell University in 2012. At Cornell, she was influenced greatly working by professor and veterinarian Lisa Fortier. Thats where Sundman said she got a good look at what true veterinary research was like.

Sundman has been a Diplomat of the American Board of Veterinary Practitioners (Equine Practice) since 2019.

Dr. Sundman brings a unique background to our program from industry and research, which will help guide our faculty in their programs, saidJohn Dascanio, senior associate dean for academic and student affairs. Combining that experience with her clinical background allows for application toward clinical practice, enabling her to serve as a great mentor to the school and to the faculty. We welcome her to her new role with the school.

Sundman joins a growing and vibrant team of faculty and staff at the School of Veterinary Medicine. Additional team members will continue to be added over the next few months as the school prepares to welcome its inaugural class in the fall of 2021.

Thanks to the generosity of Amarillo and communities across Texas, and the commitment of legislators from around the state, the Texas Tech University School of Veterinary Medicine in Amarillo was established in 2018. In September 2020, the school was granted a Letter of Reasonable Assurance, from the American Veterinary Medical Association (AVMA) Council on Education and has begun the admissions process in preparation for classes to begin in August of 2021.

The School of Veterinary Medicine will recruit and select students with a passion to serve rural and regional communities. Its curriculum is focused on the competencies and skills necessary for success in practice types that support these communities. Texas Techs innovative and cost-efficient model partners with the wider community of veterinary practices across the state to provide clinical, real-world experiential learning.

(News release from Texas Tech University)

See the rest here:
Medicine expert joins faculty of Texas Tech School of Veterinary Medicine - KLBK | KAMC | EverythingLubbock.com

Spotting a red bump in the corner of a pets eye is a concerning but not uncommon experience for many dog owners. Colloquially called cherry eye, this bump may be a prolapsed gland of the nictitans, also known as the third eyelid.

Dr. Sean Collins, a clinical assistant professor at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, says that ophthalmologists dont entirely understand why the gland of the nictating membrane sometimes protrudes from its original position but it is believed to be a result of a weakness in the connective tissue responsible for holding the gland in the correct position.

This condition can happen to any breed of dog but is seen most commonly in certain breeds, including the American cocker spaniel, English bulldog, Lhasa apso, and the Pekingese, Collins said.

Pet owners who spot a red swollen mass in the inner corner of their pets eye, large or small, should bring it to their veterinarians attention promptly. In addition to causing irritation to the dog, this condition can have lasting consequences when left untreated.

Without correction, chronic prolapse can lead to conjunctivitis (pink eye) and ocular discharge (liquid coming from the eye), Collins said. It has also been shown that with correction, dogs are less likely to develop low tear production later in life.

Low tear production can result in multiple problems if left untreated. In addition to pain and decreased vision, corneal ulceration may also develop, which can become infected and result in a ruptured eye. This condition responds well to tear stimulant therapy in most cases, but lifelong medication is usually required.

Story continues below video

Your veterinarian will be able to confirm whether your pet has cherry eye and can develop a treatment plan that works best to resolve cherry eye and reduce the potential for ocular issues as your dog ages.

Initial therapy may consist of topical anti-inflammatory therapy if local inflammation may be contributing to prolapse of the gland, he said. If a short course of medical therapy does not work or re-prolapse develops, surgical repositioning is indicated. There are numerous surgical techniques to reposition the gland with overall high success rates.

If surgical treatment is required, Collins stresses that this treatment will benefit your pet in both the short- and long-term.

Surgical repositioning is very important if initial medical therapy fails, as the gland is responsible for about 30-50% of the aqueous tear production in the dog, he said. We commonly see low tear production in the same breeds that develop a prolapsed gland of the nictitans. It has been shown that dogs with surgical repositioning of the gland have a lower chance of developing low tear production later on in life compared to those where the gland has been excised or remains chronically prolapsed.

Unfortunately, there are no known preventative measures to protect against cherry eye in dogs, Collins says. This condition can develop in both eyes, usually before the age of 2. The best way pet owners can protect their furry friend is to remain vigilant in monitoring their pets health and to bring concerns to their veterinarian promptly in case an issue does arise.

Pet Talk is a service of the College of Veterinary Medicine & Biomedical Sciences, Texas A&M University. Stories can be viewed on the web at vetmed.tamu.edu/news/pet-talk. Suggestions for future topics may be directed to editor@cvm.tamu.edu.

More here:
What to know about cherry eye in dogs - New Castle News

Two veterinarians from OSU's College of Veterinary Medicine took a measles vaccine and added the COVID-19 spike protein as a response to the global pandemic.

COLUMBUS, Ohio Ohio doctors are working to develop vaccine technology to protect us from COVID-19.

Dr. Jianrong Liand Dr. Stefan Niewiesk from Ohio State University's College of Veterinary Medicine took a measles vaccine and added the COVID-19 spike protein as a response to the global pandemic.

The resultwas a vaccine that is shown to protect against both measles and COVID-19 in at least animals.

The next step is testing humans.

The vaccine could be particularly helpful in developing countries, as it does not require the same refrigeration as the mRNA vaccines.

"We think the measles virus is a very good vaccine because it has a long-standing safety record. It has been instrumental in reducing the measles virus worldwide," Niewiesk said. "We think that given all the data it makes a very effective vaccine. Also, given the fact, it protects life-long against measles virus infections so ideally (and we do not know this yet) it would also protect for a very long time against COVID-19."

Biological E. Limited and the Ohio State Innovation Foundation announced an exclusive license agreement on Tuesday for the vaccine technology.

The company will be responsible for the evaluation and further development, including the commercialization of the vaccine candidate(s).

Translating this vaccine platform into the hands of a global vaccine company for further evaluation and development is a critical step and we are excited that Biological E has taken on this role, said Dr. Patrick Green, Associate Dean for Research and Graduate Studies, Ohio State University College of Veterinary Medicine.

Mahima Datla, Managing Director of Biological. E. Limited added, "BE has been working to develop a safe and effective vaccine for the COVID-19. BE is very happy to help further this innovation and expand that effort."

To read more about the technology, click here.

Originally posted here:
Veterinarians at OSU develop vaccine technology that could protect against COVID-19 and measles at the same time - 10TV

Purple martins on one of the new nesting box systems.

Doug Bonham, Field Data Technologies

A research team led by the Texas A&M University College of Veterinary Medicine & Biomedical Sciences (CVMBS) has been awarded a nearly $700,000 Conservation Innovation Grant from the U.S. Department of Agriculture (USDA) to develop a new artificial intelligence-based wildlife monitoring system.

The Conservation Innovation Grant program, under the USDA Natural Resources Conservation Service, supports the development of new tools, approaches, practices and technologies to further natural resource conservation on private lands.

The grant will be used by principal investigator and CVMBS associate professor Dr. Donald Brightsmith and his team to integrate camera, image and sensor data to create a tool to monitor wildlife that are typically difficult to observe, including pollinators, reptiles, amphibians and nesting birds.

Currently, landowners do not have many options for measuring their wildlife conservation efforts, such as setting up nesting boxes for birds or preserving areas of natural land, besides bringing in teams of scientists for hand surveys, a costly and lengthy process. Since private land makes up so much of the U.S., landowners efforts play a key role in the countrys overall wildlife management and conservation.

Brightsmiths team, in conjunction with colleagues from the University of California, Santa Barbara, the University of Hawaii and private industry, is working to develop a low-cost and easy-to-use system that will allow producers to monitor wildlife on their land and understand how their actions directly affect the local environment.

Part of our grant is to make it so a typical landowner can easily use a laptop or phone app to see the information that came in from a specific camera, such as where that camera is on a map; the weather, temperature, light, and humidity there; and the critters that were at that camera, Brightsmith said.

Commercial wildlife cameras already allow landowners to monitor wildlife on a small scale, but by using artificial intelligence to aggregate and analyze data from a number of cameras and locations, landowners will be able to see a much more complete picture.

The camera system will photograph the scene and, whenever there is a significant change, forward images to a central computer that will use artificial intelligence to identify species, behaviors and trends. According to Connie Woodman, a member of Brightsmiths team and graduate student in the CVMBS Department of Veterinary Pathobiology (VTPB,) this process would traditionally take scientists dozens of hours to conduct surveys and sort through photos.

Baby chickadees inside a nesting box.

Doug Bonham, Field Data Technologies

If this sort of technology could be available at low cost or free to farmers, it could really impact the ability to see if conserving farmland and private land is working, Woodman said. Its just too expensive to have a hands-on survey for every property owner who wants to apply for government support to maintain wild lands and wildlife populations.

The camera system will be used in three different setups a ground setup to monitor reptiles and amphibians, a veil trap setup for insects and a bird nesting box setup. In all three uses, the animals photographed will be free from any harm or human interference.

One of the other objectives within this is if landowners are doing land management activities like cutting, spraying, or planting, they will be able to look at the data coming in to immediately see how those changes in the ecosystem have impacted key reptiles, amphibians, birds and bees, Brightsmith said.

An early version of the nest box setup has already been deployed in the Pacific Northwest by collaborators within Field Data Technologies and is providing invaluable data on chickadee and purple martin nesting behaviors.

Its doing more than just taking photos; its spitting out data. How many eggs? When was there a change? How many times is the nest being visited? How many times does a chickadee investigate a nest box before it decides that its good enough? Woodman said. With that data we can tell a land manager, The chickadee started visiting the nest boxes X weeks before it used them. So if you wait until June to hang up the box, you wont get any use this year.'

While the grant will directly support the technologys creation and use in supporting landowners, Brightsmith hopes that the technology will one day also be adapted to create systems that could survey for invasive species and agricultural pests, monitor wildlife recovery after natural disasters, and more.

If we build a technology thats fairly straightforward to train the AI, someone else can take our platform and tweak it, he said. Our objective is to create a system that has unlimited potential.

The system will initially be tested in Arizona, California, Texas and Montana to see how it works in different environments. The team has already partnered with producers and other landowners near Austin, San Antonio and southern California to see how the technology holds up around large animals like cattle.

Along with Brightsmith and Woodman, collaborators on this grant include Drs. Chris Evelyn and Katja Seltmann, from the University of California, Santa Barbara, Cheadle Center for Biodiversity and Ecological Restoration; Dr. Ethel Villalobos, from the University of Hawaii at Manoa; and Doug Bonham, senior electronics engineer at Microsoft and the founder and president of Field Data Technologies of Essex, Montana.

Read more here:
USDA Awards Grant To Texas A&M To Develop AI-Based Wildlife Monitoring - Texas A&M University Today